Detalhe da pesquisa
1.
Drug Exposure and Minimum Inhibitory Concentration Predict Pulmonary Tuberculosis Treatment Response.
Clin Infect Dis
; 73(9): e3520-e3528, 2021 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33070176
2.
Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades.
Clin Infect Dis
; 69(8): 1394-1402, 2019 09 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30561569
3.
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.
Eur Respir J
; 54(6)2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31601711
4.
Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.
Antimicrob Agents Chemother
; 60(8): 4786-92, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27246779
5.
The diagnostic performance of GeneXpert MTB/RIF in tuberculosis meningitis: A multicentre accuracy study.
Diagn Microbiol Infect Dis
; 109(3): 116277, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38677052
6.
Second-line antituberculosis drug exposure thresholds predictive of adverse events in multidrug-resistant tuberculosis treatment.
Int J Infect Dis
; 140: 62-69, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38176643
7.
The In vitro activity of carbapenems alone and in combination with ß-lactamase inhibitors against difficult-to-treat mycobacteria; Mycobacterium tuberculosis, Mycobacterium abscessus, and Mycobacterium avium complex: A systematic review.
Int J Mycobacteriol
; 12(3): 211-225, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37721224
8.
Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis.
J Infect
; 77(6): 469-478, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30339803